Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...

Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bios autoimmune disease treatment, DR-0201, reinforcing its ...

Madness: Watch DraftKings, FanDuel, Robinhood, and Grand Canyon. CoreWeave seeks shares ranging from $47 to $55 in IPO:report ...

HighTower Advisors LLC increased its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 3.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The ...

And while it’s wreaking havoc on most stocks, some are bucking the trend, including: While markets sink, Regeneron ...

Jones Financial Companies Lllp raised its stake in Sanofi (NASDAQ:SNY – Free Report) by 55.0% during the 4th quarter, ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

The U.S. Department of Agriculture (USDA) on Thursday announced a $100M investment to combat the transmission of the bird flu virus in poultry, adding to the Trump administration's previously ...

Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid ...

Sanofi (NASDAQ:SNY – Free Report) – Equities researchers at Zacks Research lowered their Q2 2025 earnings estimates for Sanofi in a report issued on Wednesday, March 5th. Zacks Research analyst K.